Medicinal product name Revinty Ellipta
Pharmaceutical form Inhalation powder, pre-dispensed
Strength 184 µg/22 µg 
Information from the MAH on shortages Not notified
Legal status Rx Prescription (Pr.)
 Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website
ATC code R03AK10 Drugs for obstructive airway diseases

Important notice

Additional information regarding the use for persons aged 75+

If used as "DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES"
SubstanceClassComment
Fluticasoni furoasASuitable for older persons. Take into account possible systemic adverse effects. Take interactions into account.
VilanterolumASuitable for older persons. Potentiates sympathomimetic effects. May cause hypokalaemia.

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers) currently no information on availability from any wholesaler N30
(184 µg/22 µg)
Aluminium blister    EU/1/14/929/005  Summary of product characteristics, patient information leaflet and labeling text approved by the European Medicines Agency is available on European Medicines Agency website

Registration information

Marketing authorisation No. EU/1/14/929/005
Date of authorisation May 2, 2014
Marketing authorisation holder, country GlaxoSmithKline (Ireland) Limited, Ireland